Technology Core

技术核心

• 批准号: 10714508
• 负责人: David Carl Erickson
• 金额: $ 68.04万
• 依托单位: CORNELL UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-13 至 2028-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10714508
• 关键词: Address; Anemia; C-reactive protein; Cancer and Nutrition; Cervical Cancer Screening; Clinical; Collaborations; Consensus; Consultations; DNA; Decentralization; Detection; Development; Devices; Diagnostic; Direct Costs; Ecuadorian; Engineering; Evaluation; Ferritin; Funding; Funding Opportunities; General Hospitals; HIV; HPV-High Risk; Human Papillomavirus; Incubated; India; Infection; Information Dissemination; International; Iron; Lead; Leadership; Licensing; Malaria; Malignant Neoplasms; Marketing; Massachusetts; Needs Assessment; Participant; Point of Care Technology; Process; Ramp; Readiness; Research Institute; Resource Allocation; Resources; Rotation; Secure; Series; Serum; Sexually Transmitted Diseases; Structure; TFRC gene; Technology; Testing; Training; Universities; Validation; Viral load measurement; clinical research site; commercialization; early screening; experience; global health; meetings; minimally invasive; multiplex detection; nutrition; point of care; portability; programs; prototype; screening; technology development; training opportunity; training project

Point of Care Technologies for Nutrition, Infection and Cancer for Global Health (PORTENT) 3.0 Technical Core Abstract The PORTENT Technical core describes our process for advancing promising global health relevant point-of-care technologies for infection, cancer and nutrition towards clinical viability. We describe herein (1) our process for soliciting and selecting new projects from the US, our clinical partners, and from around the world, (2) how that process will be fundamentally guided by our annual needs assessment consensus, (3) how we will support team building through our partnership network, (4) how the clinical core will enable deployment and validation of the selected technologies, and (5) how the dissemination core will support: commercialization through the global health lab-to-market accelerator, training of project participants, and dissemination of results. To take maximum advantage of the resources we can deploy, at full capacity will focus on supporting 6-7 parallel projects that either are beyond the proof-of-concept stage and would benefit from clinical validation, have been validated or even commercialized domestically but are looking to expand to international settings, or have been developed/incubated by our international partners and show promise at addressing a market need in the US. Illustrative of what we will fund throughout the effort we provide four PoC project proposals originating from Cornell, Columbia, Massachusetts General Hospital, and the St. Johns Research Institute (India) that we intend to fund in year 1. These projects address specific needs which are defined in our initial needs assessment consensus and include early screening of cervical cancer, comprehensive determination of iron status enabling anemia screening, combined HIV and multiplexed detection of sexually transmitted diseases, and broader, cheaper, and more accurate malaria testing. Each of these teams will partner with at least one of our clinical sites to validate of their technologies and our dissemination core to train users workers and engage developers in clinical rotations. Beyond year 1, new and continuing will be solicited from around the world with our broadly disseminated RFP and selected based on a series pre-defined criteria which include: fit with needs assessment consensus, technological readiness, milestones, contribution to capacity building, and project team. By the end of year 5 we anticipate that we will initiate 20 independent point of care technology projects, of which 30% will originate from outside the US and 80% will transition to a larger funding opportunity, licensing arrangement or start-up company.

全球健康营养、感染和癌症护理点技术（PORTENT） 3.0技术核心 摘要 PORTENT技术核心描述了我们推进有前途的全球健康相关的过程 感染、癌症和营养的护理点技术走向临床可行性。我们在此描述 (1)我们从美国、我们的临床合作伙伴以及世界各地征集和选择新项目的过程 （2）如何在我们的年度需求评估共识的基础上指导这一进程，（3）如何 我们将通过我们的合作伙伴网络支持团队建设，（4）临床核心如何实现部署 选定的技术的验证，以及（5）传播核心将如何支持： 通过全球卫生实验室到市场加速器、培训项目参与者和传播成果。 为了最大限度地利用我们可以部署的资源，在满负荷时将重点支持6-7个并行 超出概念验证阶段并将受益于临床验证的项目， 在国内得到验证甚至商业化，但正在寻求扩展到国际环境，或者已经 由我们的国际合作伙伴开发/孵化，并显示出满足美国市场需求的承诺。 为了说明我们将在整个工作中提供什么样的资金，我们提供了四个可持续发展的项目提案， 康奈尔大学、哥伦比亚大学、马萨诸塞州总医院和圣约翰研究所（印度）， 打算在第一年提供资金。这些项目解决了我们最初需求中定义的特定需求 评估共识，包括早期筛查宫颈癌，全面确定 铁的状况使贫血筛查，艾滋病毒和性传播疾病的多重检测相结合 疾病，以及更广泛，更便宜，更准确的疟疾检测。每个团队都将与 至少有一个我们的临床研究中心，以验证他们的技术和我们的传播核心，以培训用户和工作人员 并让开发人员参与临床轮换。在第一年之后，新的和持续的将从世界各地征求意见。 我们广泛传播的RFP，并根据一系列预定义的标准进行选择，其中包括： 与需求评估共识、技术准备、里程碑、对能力建设的贡献，以及 项目团队。到第五年年底，我们预计将启动20个独立的护理点 技术项目，其中30%将来自美国以外，80%将过渡到更大的 融资机会、许可安排或初创公司。